-$0.46 Earnings Per Share Expected for Heron Therapeutics Inc (HRTX) This Quarter

Analysts predict that Heron Therapeutics Inc (NASDAQ:HRTX) will report ($0.46) earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Heron Therapeutics’ earnings. The lowest EPS estimate is ($0.64) and the highest is ($0.28). Heron Therapeutics reported earnings of ($0.81) per share in the same quarter last year, which suggests a positive year over year growth rate of 43.2%. The firm is expected to issue its next quarterly earnings report on Thursday, May 9th.

According to Zacks, analysts expect that Heron Therapeutics will report full-year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($2.01) to ($0.98). For the next fiscal year, analysts expect that the firm will report earnings of $0.75 per share, with EPS estimates ranging from $0.07 to $2.42. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Friday, February 22nd. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.17). The business had revenue of $28.84 million for the quarter, compared to analyst estimates of $28.05 million. Heron Therapeutics had a negative net margin of 230.84% and a negative return on equity of 54.98%.

Several research firms recently weighed in on HRTX. Northland Securities restated a “buy” rating on shares of Heron Therapeutics in a report on Monday. BidaskClub lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 9th. Cantor Fitzgerald lowered shares of Heron Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, March 4th. ValuEngine lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Finally, Stifel Nicolaus restated a “buy” rating and set a $54.00 target price on shares of Heron Therapeutics in a report on Friday, February 22nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and an average price target of $51.82.

Shares of NASDAQ:HRTX traded down $0.86 during midday trading on Friday, hitting $24.09. 661,824 shares of the company’s stock traded hands, compared to its average volume of 891,577. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -9.87 and a beta of 1.57. Heron Therapeutics has a twelve month low of $21.25 and a twelve month high of $42.90.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Heron Therapeutics by 36.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after buying an additional 1,661,318 shares during the period. Vanguard Group Inc increased its position in shares of Heron Therapeutics by 36.7% in the 3rd quarter. Vanguard Group Inc now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after purchasing an additional 1,661,318 shares during the last quarter. BlackRock Inc. increased its position in shares of Heron Therapeutics by 2.8% in the 4th quarter. BlackRock Inc. now owns 4,913,006 shares of the biotechnology company’s stock worth $127,443,000 after purchasing an additional 132,207 shares during the last quarter. FIL Ltd increased its position in shares of Heron Therapeutics by 3.5% in the 3rd quarter. FIL Ltd now owns 3,063,383 shares of the biotechnology company’s stock worth $96,956,000 after purchasing an additional 103,224 shares during the last quarter. Finally, Rubric Capital Management LP increased its position in shares of Heron Therapeutics by 71.8% in the 3rd quarter. Rubric Capital Management LP now owns 1,958,850 shares of the biotechnology company’s stock worth $61,998,000 after purchasing an additional 818,603 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Story: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit